Clinical Trial Update: A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease [Phase 3]

View source ↗

Summary

A multicenter open-label trial assessing the safety of agalsidase alfa enzyme replacement therapy in Canadian Fabry disease patients; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: Shire | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-02-15